Igraine (AQSE:KING) Net Interest Income : £0.00 Mil (TTM As of . 20)

View and export this data going back to 2008. Start your Free Trial

What is Igraine Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Igraine's net interest income for the twelve months ended in . 20 was £0.00 Mil. Its net interest income for the trailing twelve months (TTM) ended in . 20 was £0.00 Mil.

Igraine Net Interest Income Historical Data

The historical data trend for Igraine's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Igraine Net Interest Income Chart

Igraine Annual Data

Trend

Net Interest Income

Igraine Semi-Annual Data

Net Interest Income

Igraine Net Interest Income Calculation

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Interest Income for the trailing twelve months (TTM) ended in . 20 was £0.00 Mil.

Igraine Net Interest Income Related Terms

Thank you for viewing the detailed overview of Igraine's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Igraine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Igraine PLC (AQSE:KING) » Definitions » Net Interest Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 Primrose Street, 8th Floor, The Broadgate Tower, London, GBR, EC2A 2EW

Website

https://www.igraineplc.com

Igraine PLC is an investment company. Its business investment is to source and develops breakthrough technologies and commercially attractive discoveries in the health, Medtech, Biotech, and life science sectors.